



EPILEPSY
FOUNDATION®

MINNESOTA

Spring 2026

EpiForum

Emerging Technologies
in Epilepsy Care

This is an industry sponsored event hosted by the Epilepsy Foundation of Minnesota. All proceeds go to support Epilepsy Foundation of Minnesota's mission. Participation does not imply endorsement of any products or services.

Program Agenda

MAY 5, 2026

5:30 PM - 8:00 PM

7760 France Ave S

Bloomington, MN

5:30 - 6:30 PM

Check-in & Networking

6:30 - 8:00 PM

EpiForum Program & Discussion

**Join us for our Fall
EpiForum in
October, 2026**

More details
coming soon!



Featuring Keynote Speaker:
Gregory A. Worrell, M.D., Ph.D.
Mayo Clinic, Rochester MN

Emerging Technologies in Epilepsy Care:

What's Here, What's Next, and What It Means for Clinical Practice

Emerging technologies in epilepsy care are transforming how we understand and treat the disorder—from episodic seizure management to continuous monitoring and modulation of brain networks. Current therapies such as deep brain stimulation and responsive neurostimulation have demonstrated that electrical modulation of distributed circuits can reduce seizures, but remain limited by incomplete sensing and trial-and-error programming.

New advances in implantable and wearable sensors now enable long-term, real-world tracking of brain activity, behavior, and physiology, revealing that seizures follow predictable biological rhythms rather than occurring randomly. These insights are driving the development of seizure forecasting, adaptive neuromodulation, and AI-guided therapy optimization, allowing treatments to be personalized and delivered at the right time and place.

Looking ahead, innovations such as network biomarkers, closed-loop systems, and even cell-specific optogenetic approaches promise to shift epilepsy care toward proactive, data-driven management of brain states, with the potential to improve not only seizure control but also cognition, mood, and overall quality of life.

KEY NOTE SPEAKER

Gregory A. Worrell, M.D., Ph.D

Dr. Worrell is the William L. McKnight-3M Professor of Neuroscience at Mayo Clinic, where he leads efforts to transform epilepsy care through intelligent bioelectronic systems. His work integrates implantable brain sensing, adaptive stimulation, and AI to decode and control pathological brain networks, advancing a future of autonomous neuromodulation and precision therapies for brain disease.



GUEST SPEAKER

Aisha Abdulrazaq, M.D.

Dr. Abdulrazaq is an assistant professor of neurology and an adult epileptologist at the University of Minnesota specializing in the care of people with drug-resistant epilepsy, with a focus on women across the reproductive lifespan. She completed medical school at the University of Lagos, Nigeria, followed by neurology residency training at the University of Missouri-Columbia, and an epilepsy fellowship with advanced training in epilepsy surgery and neuromodulation at Mayo Clinic, Rochester. Her training across health system has strongly shaped her commitment to equitable epilepsy care and global neurology, with a focus on reducing structural barriers that limit access to advanced diagnostics and surgical treatment for underserved populations.



FACILITATORS

Sandipan Pati, M.D., FAES

Dr. Sandipan Pati is a board-certified epileptologist and neurophysiologist leading innovation in epilepsy care. Trained at Barrow Neurological Institute, Phoenix and Massachusetts General Hospital, Boston he directs the University of Minnesota Comprehensive Epilepsy Program, advancing surgical epilepsy and neuromodulation through intracranial electrophysiology, precision stimulation, and circuit-based therapies for intractable epilepsy.



Patricia E. Penovich, M.D.

Dr. Penovich is an Emeritus member of the Minnesota Epilepsy Group PA in St. Paul, Minnesota, and an Adjunct Clinical Professor in the Department of Neurology at the University of Minnesota. She is an adult epileptologist. She chairs the Professional Advisory Board and serves on the Board of Directors of the Epilepsy Foundation of Minnesota and serves on the Professional Advisory Board of the Epilepsy Foundation of America.



She received her neurology training and a pharmacology fellowship at the University of Rochester in Rochester, New York. Her epilepsy and EEG fellowships occurred at the University of Rochester and the University of Minnesota. She is board certified in Neurology (USA) and Neurology with special certification in epilepsy (USA).

THANK YOU

FOR JOINING US TODAY

Special Thank You to
EpiForum Planning
Committee Members:

Katherine Nickels, MD
Sima Patel, MD, FAES, FANA
Sandipan Pati, MD, FAES
Patricia Penovich, MD
Kinshuk Sahaya, MD, MBA

This event is made possible by the generous support of our sponsors.



Aucta Pharmaceuticals is a formulation-focused pharmaceutical company with a strong emphasis in precision dosage forms with a focus in CNS disorders. Aucta is excited to announce our first branded product, Motpoly XR which is a once-a-day formulation of lacosamide.



SK Life Science is a U.S. company advancing treatments that address the unmet needs of people living with CNS disorders and cancer. Together with its parent company, SK Biopharmaceuticals, SK Life Science is leveraging AI to accelerate innovation and improve outcomes for the patient communities we serve.



UCB is a global biopharmaceutical leader in neurology with a 30-year legacy in epilepsy, focusing on developing tailored anti-seizure medications for focal and generalized seizures. UCB's portfolio aims to achieve seizure freedom, with research focusing on rare syndromes (Dravet/Lennox-Gastaut). UCB's approach combines pharmaceutical innovation with patient support to manage the complex, daily challenges of living with epilepsy.



Jazz Pharmaceuticals.

At Jazz Pharmaceuticals, our purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare diseases — often with limited or no therapeutic options — so they can live their lives more fully. We have a diverse portfolio of marketed medicines including leading therapies addressing rare epilepsies, cancers and sleep disorders.

And

Xenon Pharmaceuticals

Neurelis

Medtronic